vs
Side-by-side financial comparison of American Homes 4 Rent (AMH) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $455.0M, roughly 1.5× American Homes 4 Rent). American Homes 4 Rent runs the higher net margin — 31.7% vs -104.7%, a 136.4% gap on every dollar of revenue. On growth, American Homes 4 Rent posted the faster year-over-year revenue change (4.2% vs -3.7%). American Homes 4 Rent produced more free cash flow last quarter ($823.7M vs $-94.7M). Over the past eight quarters, American Homes 4 Rent's revenue compounded faster (3.6% CAGR vs -2.9%).
American Homes 4 RentAMHEarnings & Financial Report
American Homes 4 Rent, doing business as AMH, is a real estate investment trust based in Las Vegas, Nevada, that invests in single-family rental homes. As of December 31, 2019, the company owned 52,552 homes in 22 states. Its largest concentrations are in Atlanta, Dallas-Fort Worth, and Charlotte, North Carolina.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
AMH vs QDEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $455.0M | $699.9M |
| Net Profit | $144.3M | $-733.0M |
| Gross Margin | — | — |
| Operating Margin | — | -100.7% |
| Net Margin | 31.7% | -104.7% |
| Revenue YoY | 4.2% | -3.7% |
| Net Profit YoY | 0.3% | -3583.4% |
| EPS (diluted) | $0.33 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $455.0M | — | ||
| Q3 25 | $478.5M | $699.9M | ||
| Q2 25 | $457.5M | $613.9M | ||
| Q1 25 | $459.3M | $692.8M | ||
| Q4 24 | $436.6M | $707.8M | ||
| Q3 24 | $445.1M | $727.1M | ||
| Q2 24 | $423.5M | $637.0M | ||
| Q1 24 | $423.6M | $711.0M |
| Q4 25 | $144.3M | — | ||
| Q3 25 | $116.8M | $-733.0M | ||
| Q2 25 | $123.6M | $-255.4M | ||
| Q1 25 | $128.7M | $-12.7M | ||
| Q4 24 | $143.9M | $-178.4M | ||
| Q3 24 | $87.6M | $-19.9M | ||
| Q2 24 | $108.5M | $-147.7M | ||
| Q1 24 | $128.1M | $-1.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | -100.7% | ||
| Q2 25 | — | -29.4% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | -18.4% | ||
| Q1 24 | — | -247.3% |
| Q4 25 | 31.7% | — | ||
| Q3 25 | 24.4% | -104.7% | ||
| Q2 25 | 27.0% | -41.6% | ||
| Q1 25 | 28.0% | -1.8% | ||
| Q4 24 | 33.0% | -25.2% | ||
| Q3 24 | 19.7% | -2.7% | ||
| Q2 24 | 25.6% | -23.2% | ||
| Q1 24 | 30.2% | -239.9% |
| Q4 25 | $0.33 | — | ||
| Q3 25 | $0.27 | $-10.78 | ||
| Q2 25 | $0.28 | $-3.77 | ||
| Q1 25 | $0.30 | $-0.19 | ||
| Q4 24 | $0.33 | $-2.54 | ||
| Q3 24 | $0.20 | $-0.30 | ||
| Q2 24 | $0.25 | $-2.20 | ||
| Q1 24 | $0.30 | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.5M | $98.1M |
| Total DebtLower is stronger | $5.1B | $2.5B |
| Stockholders' EquityBook value | $7.0B | $2.0B |
| Total Assets | $13.2B | $5.7B |
| Debt / EquityLower = less leverage | 0.72× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.5M | — | ||
| Q3 25 | $45.6M | $98.1M | ||
| Q2 25 | $323.3M | $151.7M | ||
| Q1 25 | $69.7M | $127.1M | ||
| Q4 24 | $199.4M | $98.3M | ||
| Q3 24 | $162.5M | $143.7M | ||
| Q2 24 | $718.4M | $107.0M | ||
| Q1 24 | $124.8M | $78.5M |
| Q4 25 | $5.1B | — | ||
| Q3 25 | $4.8B | $2.5B | ||
| Q2 25 | $5.2B | $2.1B | ||
| Q1 25 | $4.9B | $2.1B | ||
| Q4 24 | $5.0B | $2.1B | ||
| Q3 24 | $4.5B | $2.2B | ||
| Q2 24 | $5.0B | $2.2B | ||
| Q1 24 | $4.5B | $2.2B |
| Q4 25 | $7.0B | — | ||
| Q3 25 | $7.2B | $2.0B | ||
| Q2 25 | $7.2B | $2.8B | ||
| Q1 25 | $7.2B | $3.0B | ||
| Q4 24 | $7.2B | $3.0B | ||
| Q3 24 | $7.0B | $3.2B | ||
| Q2 24 | $7.0B | $3.2B | ||
| Q1 24 | $7.0B | $3.3B |
| Q4 25 | $13.2B | — | ||
| Q3 25 | $13.3B | $5.7B | ||
| Q2 25 | $13.6B | $6.4B | ||
| Q1 25 | $13.3B | $6.5B | ||
| Q4 24 | $13.4B | $6.4B | ||
| Q3 24 | $12.8B | $6.8B | ||
| Q2 24 | $13.3B | $6.7B | ||
| Q1 24 | $12.8B | $6.7B |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.68× | 1.23× | ||
| Q2 25 | 0.72× | 0.74× | ||
| Q1 25 | 0.69× | 0.70× | ||
| Q4 24 | 0.70× | 0.72× | ||
| Q3 24 | 0.64× | 0.68× | ||
| Q2 24 | 0.71× | 0.70× | ||
| Q1 24 | 0.64× | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $864.3M | $-45.5M |
| Free Cash FlowOCF − Capex | $823.7M | $-94.7M |
| FCF MarginFCF / Revenue | 181.0% | -13.5% |
| Capex IntensityCapex / Revenue | 8.9% | 7.0% |
| Cash ConversionOCF / Net Profit | 5.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.5B | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $864.3M | — | ||
| Q3 25 | $223.3M | $-45.5M | ||
| Q2 25 | $271.9M | $-46.8M | ||
| Q1 25 | $223.4M | $65.6M | ||
| Q4 24 | $811.5M | $63.7M | ||
| Q3 24 | $233.6M | $117.9M | ||
| Q2 24 | $274.0M | $-97.9M | ||
| Q1 24 | $201.8M | $-700.0K |
| Q4 25 | $823.7M | — | ||
| Q3 25 | $214.5M | $-94.7M | ||
| Q2 25 | $257.7M | $-84.3M | ||
| Q1 25 | $215.9M | $9.4M | ||
| Q4 24 | $777.5M | $16.5M | ||
| Q3 24 | $225.3M | $71.4M | ||
| Q2 24 | $263.3M | $-133.2M | ||
| Q1 24 | $191.0M | $-66.8M |
| Q4 25 | 181.0% | — | ||
| Q3 25 | 44.8% | -13.5% | ||
| Q2 25 | 56.3% | -13.7% | ||
| Q1 25 | 47.0% | 1.4% | ||
| Q4 24 | 178.1% | 2.3% | ||
| Q3 24 | 50.6% | 9.8% | ||
| Q2 24 | 62.2% | -20.9% | ||
| Q1 24 | 45.1% | -9.4% |
| Q4 25 | 8.9% | — | ||
| Q3 25 | 1.8% | 7.0% | ||
| Q2 25 | 3.1% | 6.1% | ||
| Q1 25 | 1.6% | 8.1% | ||
| Q4 24 | 7.8% | 6.7% | ||
| Q3 24 | 1.9% | 6.4% | ||
| Q2 24 | 2.5% | 5.5% | ||
| Q1 24 | 2.6% | 9.3% |
| Q4 25 | 5.99× | — | ||
| Q3 25 | 1.91× | — | ||
| Q2 25 | 2.20× | — | ||
| Q1 25 | 1.74× | — | ||
| Q4 24 | 5.64× | — | ||
| Q3 24 | 2.67× | — | ||
| Q2 24 | 2.52× | — | ||
| Q1 24 | 1.58× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMH
Segment breakdown not available.
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
